Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03796273
Recruitment Status : Recruiting
First Posted : January 8, 2019
Last Update Posted : June 27, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors.

Condition or disease Intervention/treatment Phase
Anatomic Stage IV Breast Cancer AJCC v8 Astrocytoma Breast Carcinoma Metastatic in the Brain Glioma Invasive Breast Carcinoma Oligodendroglioma Prognostic Stage IV Breast Cancer AJCC v8 Recurrent Glioma Other: Best Practice Drug: Ketoconazole Early Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine if ketoconazole alters the tGLI1 activation signature (tGAS) which is consisted of eight validated tGLI1 regulated genes (CD24, CD44, VEGF-A, VEGF-C, VEGFR2, TEM7, OCT-4. and heparanase) in tGLI1 expressing brain biospecimens.

SECONDARY OBJECTIVES:

I. To determine if pre-treatment with ketoconazole, an inhibitor of the tGLI1 pathway in tissue culture and animal models, reduces circulating tGLI1 associated exosomal miRNA expression (miR1290 and miR1246) in brain tumor patients.

II. To describe the safety of ketoconazole when administered peri-operatively to patients with primary and secondary brain tumors.

III. To measure the blood brain penetrance of ketoconazole in serum relative to enhancing brain tissue.

EXPLORATORY OBJECTIVES:

I. To measure blood brain penetration of ketoconazole in serum relative to cerebrospinal fluid (CSF) and serum relative to non-enhancing brain tissue (exploratory recurrent glioma patients only).

II. To compare tGLI1 expression and pathway modulation with ketoconazole pre-treatment in patients with recurrent gliomas relative to breast cancer brain metastases (BCBM).

III. To determine the overall survival and toxicity outcomes for patients that continue ketoconazole after surgery, at the discretion of the treating physician.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ketoconazole orally (PO) once daily (QD) on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo standard surgery.

After completion of study treatment, patients are followed up at 30 days.


Layout table for study information
Study Type : Interventional
Estimated Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study
Actual Study Start Date : March 13, 2019
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : February 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm I (ketoconazole)
Patients receive ketoconazole PO QD on days 1-4 before standard surgery in the absence of disease progression or unacceptable toxicity.
Other: Best Practice
Undergo standard surgery
Other Names:
  • standard of care
  • standard therapy

Drug: Ketoconazole
Given PO
Other Names:
  • Fungarest
  • Fungoral
  • Ketoderm
  • Ketoisdin
  • Nizoral
  • Orifungal M
  • Panfungol
  • R-41400
  • Xolegel

Active Comparator: Arm II (standard surgery)
Patients undergo standard surgery.
Other: Best Practice
Undergo standard surgery
Other Names:
  • standard of care
  • standard therapy




Primary Outcome Measures :
  1. tGLI1 activation signature 8 (t-GAS 8) [ Time Frame: Up to 30 days after surgery ]
    The primary outcome of this study is modulation of the tGLI1 pathway as assessed by the tGLI1 activation signature 8 (t-GAS 8) [29, 40]. t-GAS 8 consists of eight validated tGLI1 regulated genes (CD24, CD44, VEGF-A, VEGF-C, VEGFR2, TEM7, OCT-4. and heparanase) and is measured using qPCR in patients whose brain tissue expresses tGLI1 (by IHC). The distribution of the tGAS will be examined and transformed to approximate the conditional normality assumption if necessary. Analysis of variance (ANOVA) methods will be used to determine the effects of different factors of interest (e.g., treatment or tumor type) on the outcomes measured.


Secondary Outcome Measures :
  1. tGLI1 pathway activation [ Time Frame: Up to 30 days after surgery ]
    tGLI1 pathway activation will be compared between treatment groups using ANOVA as described for the analysis of primary objective.

  2. Incidence of adverse events (AEs) [ Time Frame: Up to 30 days after surgery ]
    The safety of ketoconazole will be defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 criteria and determined by adverse event proportions. The adverse event proportions will be compared between treatment groups using chi-squared tests. If feasible, a logistic regression model will be used to detect whether the adverse event proportion is higher in the treatment group after adjusting for the tumor type.

  3. Blood brain penetrance of ketoconazole in serum relative to enhancing brain tissue [ Time Frame: Up to 30 days after surgery ]
    The analysis will be the same as that for the analysis of primary objective.


Other Outcome Measures:
  1. Serum ketoconazole concentrations in Cerebrospinal Fluid (CSF) [ Time Frame: Up to 30 days after surgery ]
    Measured using mass spectroscopy. The analysis will be the same as that for the analysis of primary objective. If the sample size is too small, the nonparametric approach will be considered as the primary analysis.

  2. Serum ketoconazole concentrations in enhancing brain tissue [ Time Frame: Up to 30 days after surgery ]
    Measured using mass spectroscopy. The analysis will be the same as that for the analysis of primary objective. If the sample size is too small, the nonparametric approach will be considered as the primary analysis.

  3. Serum ketoconzcole concentrations in unenhancing brain tissue [ Time Frame: Up to 30 days after surgery ]
    Measured using mass spectroscopy. The analysis will be the same as that for the analysis of primary objective. If the sample size is too small, the nonparametric approach will be considered as the primary analysis.

  4. Changes in tGLI1 signaling pathway [ Time Frame: Baseline up to 30 days after surgery ]
    Will be calculated and compared between treatment groups. Ideally analysis of covariance should be done. However, due to the small sample size, ANOVA as described for the primary analysis approach or the 2-sample t test will be used. If needed, non-parametric approaches will be used instead.

  5. Overall survival (OS) [ Time Frame: From the date of the starting ketoconazole to the date of death from any cause, assessed up to 30 days after ketoconazole treatment completion ]
    The Kaplan-Meier method will be used to estimate OS probability and median time of survival along with the 95% confidence interval.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have a history of:

    • Histologically confirmed primary breast cancer including primary invasive and metastatic breast cancers with imaging findings consistent with brain metastasis. In the event that a patient presents with an initial diagnosis of metastatic breast cancer with imaging findings of a new brain metastases and unequivocal imaging findings of a primary breast cancer, consideration for study enrollment requires approval from the study chair (primary cohort)

OR

  • Histologically confirmed primary glioma including astrocytoma or oligodendroglioma of any World Health Organization grade with imaging findings consistent with recurrent or progressive disease (exploratory cohort). Patients with ependymoma will not be included.

    • Subjects must be undergoing surgical resection for clinical purposes with anticipated resection of at least 300 mg of tissue.
    • Patients with any prior number of radiation (including brain radiation), chemotherapy, or surgical interventions will be eligible for this protocol.
    • The effects of ketoconazole on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
    • Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria:

  • Subjects with contraindication to ketoconazole including:

    • Prior allergic reaction or intolerance of ketoconazole
    • Known active hepatitis
    • QTc prolongation (based on electrocardiography [EKG] obtained within 21 days of enrollment, with a threshold of >450 ms in males and >470 ms in female)
    • Known liver cirrhosis will be excluded from enrollment
    • Positive serum pregnancy test within 21 days of enrollment
  • Subjects currently taking medications that are included in the contraindicated concurrent medications section of the Food and Drug Administration (FDA) approved indications for ketoconazole will be required to complete a seven day wash out period prior to consideration for enrollment.
  • Subjects for whom collection of blood, or tissue samples is unsafe or clinically inadvisable.
  • Pregnant women are excluded from this study because ketoconazole is a Class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ketoconazole, breastfeeding should be discontinued if the mother is treated with ketoconazole.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03796273


Locations
Layout table for location information
United States, North Carolina
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Roy E. Strowd    336-716-7422    rstrowd@wakehealth.edu   
Principal Investigator: Roy E. Strowd         
Sponsors and Collaborators
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Roy Strowd Wake Forest University Health Sciences

Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT03796273     History of Changes
Other Study ID Numbers: IRB00054587
NCI-2018-03087 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CCCWFU 91118 ( Other Identifier: Wake Forest University Health Sciences )
P30CA012197 ( U.S. NIH Grant/Contract )
First Posted: January 8, 2019    Key Record Dates
Last Update Posted: June 27, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Carcinoma
Breast Neoplasms
Astrocytoma
Oligodendroglioma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Ketoconazole
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors